| ZFIN ID: ZDB-PERS-220920-4 |
Djouad, Farida
|
|
BIOGRAPHY AND RESEARCH INTERESTS
SCIENTIFIC EXPERIENCE
Since 2021 Research director (DR2), INSERM U1183, Montpellier, France
2013-2020 Research associate (CR1), INSERM U844/U1183, Montpellier, France
2009-2012 Research associate (CR2), INSERM U844, INM, Montpellier, France
2006-2008 Post-doctoral fellow, NIAMS, NIH, Bethesda, USA
EDUCATION
2012- Accreditation to Direct Research (HDR), University of Montpellier
2006- Ph.D. Biology and Health, University of Montpellier (First class honours)
2001- Advance degree in Biology and Health, University of Montpellier, France
2000- B.sc and M.sc in Biochemistry, University of Montpellier, France
I am a Research Director at INSERM, in charge of the group "Mechanisms of Regeneration and Therapeutic Applications" at the Institute of Regenerative Medicine and Biotherapies (IRMB). With my group we were among the first to discover the immunoregulatory properties of mesenchymal stem cells in 2002. Since, I have been interested in the mechanisms underlying these immunoregulatory properties and in the development of protocols to enhance them. I also have expertise in the zebrafish model, the study of macrophage biology during aseptic and non-aseptic wounds and the study of mechanisms associated with tissue regeneration. With my group, I have identified for the first time, through the generation of double transgenic lines, macrophage subtypes in zebrafish and determined their specific roles during the regeneration process. Thanks to this expertise, I have developed several collaborative projects with academic and industrial partners in order to model rare genetic diseases in zebrafish and to study the effect of cells or drugs on macrophage response and regeneration process.
Since 2021 Research director (DR2), INSERM U1183, Montpellier, France
2013-2020 Research associate (CR1), INSERM U844/U1183, Montpellier, France
2009-2012 Research associate (CR2), INSERM U844, INM, Montpellier, France
2006-2008 Post-doctoral fellow, NIAMS, NIH, Bethesda, USA
EDUCATION
2012- Accreditation to Direct Research (HDR), University of Montpellier
2006- Ph.D. Biology and Health, University of Montpellier (First class honours)
2001- Advance degree in Biology and Health, University of Montpellier, France
2000- B.sc and M.sc in Biochemistry, University of Montpellier, France
I am a Research Director at INSERM, in charge of the group "Mechanisms of Regeneration and Therapeutic Applications" at the Institute of Regenerative Medicine and Biotherapies (IRMB). With my group we were among the first to discover the immunoregulatory properties of mesenchymal stem cells in 2002. Since, I have been interested in the mechanisms underlying these immunoregulatory properties and in the development of protocols to enhance them. I also have expertise in the zebrafish model, the study of macrophage biology during aseptic and non-aseptic wounds and the study of mechanisms associated with tissue regeneration. With my group, I have identified for the first time, through the generation of double transgenic lines, macrophage subtypes in zebrafish and determined their specific roles during the regeneration process. Thanks to this expertise, I have developed several collaborative projects with academic and industrial partners in order to model rare genetic diseases in zebrafish and to study the effect of cells or drugs on macrophage response and regeneration process.
PUBLICATIONS
NON-ZEBRAFISH PUBLICATIONS
Original Articles
1. Sarre C, Contreras-Lopez R, Nernpermpisooth N, Barrere C, Bahraoui S, Terraza C, Tejedor G, Vincent A, Luz-Crawford P, Kongpol K, Kumphune S, Piot C, Nargeot J, Jorgensen C, Djouad F, Barrere-Lemaire S. PPARβ/δ priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia-reperfusion injury. Stem Cell Research and Therapy. 2022
2. Bodic B, Boutet MA, Boyer C, Metayer B, Vignes C, Lesoeur J, Veziers J, Daguin V, Haspot F, Maugars Y, Djouad F, Guicheux J, Vinatier C. Development and characterization of a humanized mouse model of osteoarthritis. Osteoarthritis Cartilage. 2022
3. Charrier M, Lorant J, Contreras-Lopez R, Tejedor G, Blanquart C, lieubeau F, schleder C, Leroux I, Deshayes S, Fonteneau JF, Babarit C, Hamel A, Magot A, Pereon Y, Viau S, Delorme B, Luz-Crawford P, Lamirault G, Djouad F, Rouger K. Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathways. Stem Cell Research and Therapy. 2022
4. Contreras-Lopez RA, Elizondo-Vega R, Luque-Campos N, Torres MJ, Pradenas C, Tejedor G, Paredes-Martínez MJ, Vega-Letter AM, Campos-Mora M, Rigual-Gonzalez Y, Oyarce K, Salgado M, Jorgensen C, Khoury M, Garcia-Robles MA, Altamirano C, Djouad F, Luz-Crawford P. ATP synthase inhibitor induces an AMPK-dependent metabolic rewiring of MSC leading to an enhanced immunosuppressive potential. Theranostics. 2021
5. Riquier S, Mathieu M, Bessiere C, Boureux A, Ruffle F, Lemaitre JM, Djouad F, Gilbert N, Commes T. Long non-coding RNA exploration for mesenchymal stem cell characterisation. BMC Genomics. 2021
6. Tejedor G, Luz-Crawford P, Barthelaix A, Toupet K, Roudières S, Autelitano F, Jorgensen C, Djouad F. MANF Produced by MRL Mouse-Derived Mesenchymal Stem Cells Is Pro-regenerative and Protects From Osteoarthritis. Front Cell Dev Biol. 2021
7. Nernpermpisooth N, Sarre C, Barrere C, Contreras R, Luz-Crawford P, Tejedor G, Vincent A, Piot C, Kumphune S, Nargeot J, Jorgensen C, Barrère-Lemaire S, Djouad F. PPARβ/δ Is Required for Mesenchymal Stem Cell Cardioprotective Effects Independently of Their Anti-inflammatory Properties in Myocardial Ischemia-Reperfusion Injury. Front Cardiovasc Med. 2021
8. Tejedor G, Contreras-Lopez R, Barthelaix A, Ruiz M, Noël D, De Ceuninck F, Pastoureau P, Luz-Crawford P, Jorgensen C, Djouad F. Pyrroline-5-Carboxylate Reductase 1 Directs the Cartilage Protective and Regenerative Potential of Murphy Roths Large Mouse Mesenchymal Stem Cells. Front Cell Dev Biol. 2021
9. Contreras-Lopez R, Elizondo-Vega R, Paredes MJ, Luque-Campos N, Torres MJ, Tejedor G, Vega-Letter AM, Figueroa-Valdés A, Pradenas C, Oyarce K, Jorgensen C, Khoury M, Garcia-Robles MLA, Altamirano C, Luz-Crawford P*, Djouad F*. HIF1α-dependent metabolic reprogramming governs mesenchymal stem/stromal cell immunoregulatory functions. FASEB J. 2020.
10. Kurte M, Vega-Letter AM, Luz-Crawford P, Djouad F, Noël D, Khoury M, Carrión F. Stem Cell Res Ther. 2020 Sep 25;11(1):416. doi: 10.1186/s13287-020-01840-2.
11. Contreras-Lopez RA, Elizondo-Vega R, Torres MJ, Vega-Letter AM, Luque-Campos N, Paredes-Martinez MJ, Pradenas C, Tejedor G, Oyarce K, Salgado M, Jorgensen C, Khoury M, Kronke G, Garcia-Robles MA, Altamirano C, Luz-Crawford P, Djouad F. PPARβ/δ-dependent MSC metabolism determines their immunoregulatory properties. Scientific Reports. 2020.
12. Müller DIH, Stoll C, Palumbo-Zerr K, Böhm C, Krishnacoumar B, Ipseiz N, Taubmann J, Zimmermann M, Böttcher M, Mougiakakos D, Tuckermann J, Djouad F, Schett G, Scholtysek C, Krönke G. PPARδ-mediated mitochondrial rewiring of osteoblasts determines bone mass. Scientific Reports. 2020.
13. Tejedor G, Laplace-Builhé, Luz-Crawford, Assou S, Barthelaix A, Kissa K, Jorgensen C, Collignon J, Chuchana P, Djouad F. Tbx1 and Fgf11 are alongside Sox6 and Sox9 part of a gene network that regulates forelimb development. Scientific Reports. 2020.
14. Sanchez E, Laplace-Builhé B, …, Djouad F, Geneviève D. POLR1B and neural crest cells anomalies in Treacher Collins syndrome type 4. Genetics in Medicine. 2020.
15. Luz-Crawford P, Javier Hernandez F, Djouad F, Luque-Campos N, Caceido A, Carrère Kremer S, Brondello JM, Vignais ML, Pène J and Jorgensen C. Mesenchymal stem cell repression of Th17 cells is triggered by mitochondrial transfer. Stem Cell Res Ther. 2019.
16. Hyenne V, Ghoroghi S, Collot M, Bons J, Follain G, Harlepp S, Mary B, Bauer J, Mercier L, Busnelli I, Lefebvre O, Fekonja N, Garcia-Leon MJ, Machado P, Delalande F, López AA, Silva SG, Verweij FJ, van Niel G, Djouad F, Peinado H, Carapito C, Klymchenko AS, Goetz JG. Studying the Fate of Tumor Extracellular Vesicles at High Spatiotemporal Resolution Using the Zebrafish Embryo. Dev Cell. 2019.
17. Kurte M, Luz-Crawford P, Vega-Letter AM, Contreras RA, Tejedor G, Elizondo-Vega R, Martinez-Viola L, Fernández-O'Ryan C, Figueroa FE, Jorgensen C, Djouad F, Carrión F. IL17/IL17RA as a Novel Signaling Axis Driving Mesenchymal Stem Cell Therapeutic Function in Experimental Autoimmune Encephalomyelitis. Front Immunol. 2018.
18. Chuchana P, Mausset-Bonnefont AL, Mathieu M, Espinoza F, Teigell M, Toupet K, Ripoll C, Djouad F, Noel D, Jorgensen C, Brondello JM. Secreted α-Klotho maintains cartilage tissue homeostasis by repressing NOS2 and ZIP8-MMP13 catabolic axis. Aging. 2018.
19. Luz-Crawford P, Espinosa-Carrasco G, Ipseiz N, Contreras R, Tejedor G, Medina DA, Vega-Letter AM, Ngo D, Morand EF, Pène J, Hernandez J, Jorgensen C, Djouad F. Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell Interplay. Theranostics. 2018 Jan.
20. Luz-Crawford P, Ipseiz N, Espinosa-Carrasco G, Caicedo A, Tejedor G, Toupet K, Loriau J, Scholtysek C, Stoll C, Khoury M, Noël D, Jorgensen C, Krönke G, Djouad F. PPARβ/δ directs the therapeutic potential of mesenchymal stem cells in arthritis. Ann Rheum Dis. 2016 Feb.
21. Luz-Crawford P, Torres MJ, Noël D, Fernandez A, Toupet K, Alcayaga-Miranda F, Tejedor G, Jorgensen C, Illanes SE, Figueroa FE, Djouad F, Khoury M. The Immunosuppressive Signature of Menstrual Blood Mesenchymal Stem Cells Entails Opposite Effects on Experimental Arthritis and Graft Versus Host Diseases. Stem Cells. 2016 Feb.
22. Luz-Crawford P, Djouad F, Toupet K, Fontesa M, Hoodjuing M, Jorgensen C, Noël D. Mesenchymal stem cell-derived IL1RA promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. 2016 Dec.
23. Luz-Crawford P, Tejedor G, Mausset-Bonnefont AL, Beaulieu E, Morand EF, Jorgensen C, Noël D, Djouad F. Gilz governs the therapeutic potential of mesenchymal stem cells by inducing a switch from pathogenic to regulatory Th17 cells. Arthritis Rheumatol. 2015 Feb.
24. Rackwitz L, Djouad F, Janjanin S, Nöth U, Tuan RS. Functional cartilage repair capacity of de-differentiated, chondrocyte- and mesenchymal stem cell-laden hydrogels in vitro. Osteoarthritis Cartilage. 2014 Jun.
25. Djouad F, Tejedor G, Toupet K, Maumus M, Bony C, Blangy A, Chuchana P, Jorgensen C, Noël D. Promyelocytic leukemia zinc-finger induction signs mesenchymal stem cell commitment: identification of a key marker for stemness maintenance? Stem Cell Res Ther. 2014 Feb. Stem cell res and ther.
26. Mathieu M, Iampietro M, Chuchana P, Guérit D, Djouad F, Noël D, Jorgensen C. Involvement of angiopoietin-like 4 in matrix remodeling during chondrogenic differentiation of mesenchymal stem cells. J Biol Chem. 2014 Mar.
27. Scholtysek C, Katzenbeisser J, Fu H, Uderhardt S, Ipseiz N, Stoll C, Zaiss MM, Stock MI, Donhauser L, Böhm C, Kleyer A, Hess A, Engelke K, David JP, Djouad F, Tuckermann JP, B. Desvergne, Schett G and Krönke G. PPARβ governs Wnt signaling and bone turnover. Nat. Med. 2013 May.
28. Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova- Lamperti E, Tejedor G, Noël D, Jorgensen C, Figueroa F, Djouad F, Carrión F. MSCs generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013 Jun.
29. Luz-Crawford P., Noël D., Contreras López R., Figueroa F., Carrión F., Jorgensen C., Djouad F. MSC repress Th17 molecular program through the PD-1 pathway. PLoSONE. 2012.
30. Jackson WM, Lozito T, Djouad F, Kuhn NZ, Nesti LJ, Tuan RS. Differentiation and regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue. J Cell Mol Med. 2011.
31. Djouad F, Jackson WM, Bobick BE, Huang GT, Janjanin S, Song Y, Tuan RS. Activin A expression regulates multipotency of mesenchymal progenitor cells. Stem cell res and ther.
32. Huang GT, Yamaza T, Shea LD, Djouad F, Kuhn NZ, Tuan RS, Shi S. Stem/Progenitor cell-mediated de novo regeneration of dental pulp with newly deposited continuous layer of dentin in an in vivo model. Tissue Engineering, Part A. 2010.
33. Djouad F, Rackwitz L, Song Y, Janjanin S, Tuan RS. Pro-inflammatory cytokines activate ERK1/2 pathway and compromise integration of chondrocyte-laden hydrogels into articular cartilage, Tissue Engineering, Part A. 2009.
34. Djouad F, Bony C, Canovas F, Fromigué O, Rème T, Jorgensen C, Noël D. Transcriptomic analysis identifies Foxo3A as a novel transcription factor regulating mesenchymal stem cell chondrogenic differentiation. Cloning Stem Cells. 2009.
35. Jackson WM, Aragon AB, Djouad F, Song Y, Koehler SM, Nesti LJ, Tuan RS. Mesenchymal progenitor cells derived from traumatized human muscle. Journal of Tissue Engineering and Regenerative Medicine. 2009.
36. Gordeladze JO, Djouad F, Brondello JM, Noël D, Duroux-Richard I, Apparailly F, Jorgensen C. Concerted stimuli regulating osteo-chondral differentiation from stem cells: phenotype acquisition regulated by microRNAs. Acta Pharmacologica Sinica, 2009.
37. Djouad F, Janjanin S, Shanty RM, Baksh D, Gollapudi K, Prgomet D, Rackwitz L, Joshi AS, Tuan RS. Human Palatine Tonsil: a New Tissue Source of Multipotent Mesenchymal Progenitor Cells. Arthritis Res. Ther. 2008.
38. Djouad F, Charbonnier L, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C, Noël D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an IL-6-dependent mechanism. Stem Cells. 2007.
39. Djouad F., Delorme B., Maurice M., Bony C., Apparailly F., Louis-Plence P., Canovas F, Charbord P., Jorgensen C., Noël D. Mesenchymal stem cell differentiation towards chondrocytes is associated with changes of their microenvironment. Arthritis Res. Ther. 2007.
40. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noël D. Earlier onset of syngeneic tumours in presence of mesenchymal stem cells. Transplantation. 2006.
41. Djouad F, Bony C, Haüpl T, Uze G, Lahlou N, Plence P, Apparailly F, Canovas F, Rème T, Sany J, Jorgensen C, Noël D. Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res. Ther. 2005.
42. Djouad F, Fritz V, Apparailly F, Plence P, Bony C, Sany J, Jorgensen C, Noël D. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 2005.
43. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Jorgensen C, Noël D. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003.
44. Delbosc S, Morena M, Djouad F, Ledoucen C, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, are able to reduce superoxide anion production by NADPH oxidase THP-1-derived monocyte”. J cardiovasc Pharmacol. 2002.